Ikena Oncology (NASDAQ:IKNA - Get Free Report) issued its earnings results on Thursday, May 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.03, Zacks reports.
Ikena Oncology Trading Up 0.9%
Shares of IKNA stock traded up $0.01 during trading hours on Friday, hitting $1.11. The company's stock had a trading volume of 95,338 shares, compared to its average volume of 167,059. The business has a fifty day moving average of $1.20 and a 200-day moving average of $1.44. The stock has a market cap of $53.57 million, a price-to-earnings ratio of -0.90 and a beta of 0.47. Ikena Oncology has a twelve month low of $0.97 and a twelve month high of $1.94.
Institutional Trading of Ikena Oncology
An institutional investor recently raised its position in Ikena Oncology stock. Goldman Sachs Group Inc. grew its holdings in Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 62.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,464 shares of the company's stock after purchasing an additional 29,369 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.16% of Ikena Oncology worth $98,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 75.00% of the company's stock.
Ikena Oncology Company Profile
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Articles
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
